ProBio is a global contract development and manufacturing (CDMO) organization, which aims to accelerate the manufacturing of life-changing drugs, discover novel therapeutic targets, and develop innovative therapeutic approaches to manufacture best-in-class DNA, RNA, and protein-based therapeutics. As a global partner, ProBio brings together multi-disciplinary expertise to accelerate the manufacturing of advanced therapies, including biologics, protein and mRNA vaccines, viral vectors, antibody-drug conjugates and drug discovery services. We aid you in realizing the potential of your breakthrough discovery to treat diseases and improve lives. Let us accelerate your path to market with the greatest chance of success!
$220M sweet spot round size
2020
$220M
from 2 investors over 1 rounds
ProBio raised $220M on February 18, 2023
Investors: Legend Capital and + 6 Other investors